You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
COMPANY PROFILE
Beijing Avistone Biotechnology Co., Ltd.
Avistone is a commercial-stage innovative biopharmaceutical company, and is committed to delivering high-quality innovative drugs to oncology patients worldwide, enabling them to achieve a better quality of life.
For a decade, Avistone has been dedicated to first-in-class and best-in-class drugs, and has established a strong pipeline comprising multiple novel therapies, with several candidates in advanced global clinical development.
-
MANAGEMENT TEAM
-
BOARD OF DIRECTORS
-
SCIENTIFIC ADVISORY BOARD
-
Hepeng Shi
Founder, Chairman and CEO of Avistone
-
Peilong Zhang
Chief Technology Officer (CTO), Avistone
-
Weizhe Xue
Senior Director of Clinical Operations, Avistone
-
Gong Li
Senior Director of Medicinal Chemistry, Avistone
-
Hepeng Shi
Founder, Chairman and CEO of Avistone
-
David Liu
Managing Director of Vivo Capital
-
Renjie Wang
Managing Director of Bain Capital Life Sciences
-
Jiaqi Zheng
Partner of Primavera Capital
-
Yilong Wu
Professor
-
Tao Jiang
Professor
-
Xiuning Le
Professor
